Edesa Biotech (EDSA) Expected to Announce Quarterly Earnings on Friday

Edesa Biotech (NASDAQ:EDSA) is anticipated to announce its results before the market opens on Friday, February 13th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter.

Edesa Biotech (NASDAQ:EDSA) last issued its quarterly earnings results on Friday, December 12th. The company reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.80. The business had revenue of $0.25 million for the quarter. On average, analysts expect Edesa Biotech to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Edesa Biotech Trading Up 2.8%

Shares of EDSA opened at $1.12 on Friday. The firm has a market cap of $9.33 million, a PE ratio of -0.83 and a beta of 0.21. Edesa Biotech has a 12 month low of $0.94 and a 12 month high of $4.49. The stock has a fifty day moving average price of $1.48 and a 200-day moving average price of $1.99.

Analyst Upgrades and Downgrades

EDSA has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Edesa Biotech in a report on Monday, December 29th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Edesa Biotech in a research report on Monday, November 3rd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $5.00.

Institutional Investors Weigh In On Edesa Biotech

A hedge fund recently bought a new stake in Edesa Biotech stock. Susquehanna International Group LLP bought a new position in Edesa Biotech, Inc. (NASDAQ:EDSA) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,610 shares of the company’s stock, valued at approximately $36,000. Susquehanna International Group LLP owned about 0.21% of Edesa Biotech as of its most recent SEC filing. Hedge funds and other institutional investors own 5.50% of the company’s stock.

Edesa Biotech Company Profile

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.